BPC-157 + TB-500: Why This Stack Works and How to Run It

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Its primary mechanism is angiogenesis promotion at the site of administration - it upregulates VEGFR2 signaling to drive new blood vessel formation into damaged tissue. Secondary pathways include tendon fibroblast proliferation (via FGFR2), collagen synthesis via TGF-β upregulation, and a direct anti-inflammatory effect through modulation of the nitric oxide system.

Critically, BPC-157's effects are primarily local. Subcutaneous injection near a target tissue concentrates its angiogenic action at that site. Studies in rodent models demonstrate measurable tendon, ligament, and muscle repair within 7-14 days at 200-500 mcg/day doses.

TB-500 is a synthetic fragment of Thymosin Beta-4 spanning residues 17-23 (the LKKTET actin-binding domain). Note: Ac-SDKP is a distinct tetrapeptide fragment of Thymosin Alpha-1, not Thymosin Beta-4: the two should not be conflated. TB-500 contains the actin-binding domain responsible for TB4's regenerative effects. Its mechanism is fundamentally different from BPC-157: rather than promoting local angiogenesis, TB-500 works by sequestering monomeric G-actin - the building block of intracellular actin filaments - which modulates cell migration, differentiation, and wound healing across multiple tissue types simultaneously.

This gives TB-500 a systemic reach that BPC-157 lacks. A single subcutaneous injection distributes throughout the body, with particularly elevated uptake in muscle, connective tissue, and cardiac tissue. Plasma half-life is short (~1.2-1.5 hours), but tissue residence time is substantially longer - likely explaining the efficacy of twice-weekly dosing despite rapid clearance.

The standard loading protocol for BPC-157 is 500 mcg/day for 4-6 weeks, followed by 250 mcg/day maintenance if continuing. TB-500's loading phase is 2.5 mg twice weekly for 4-6 weeks, dropping to 2.5 mg once monthly for maintenance. The loading phase is where the most significant tissue repair signal is established - maintenance doses are designed to sustain, not rebuild.

Both compounds are typically run concurrently for the full loading phase. There is no pharmacokinetic interaction between them - BPC-157 and TB-500 work on different receptor systems and can be drawn separately and injected at the same time or at different times without consequence.